Rapport Therapeutics (RAPP) insider sells 8,500 shares in Rule 10b5-1 trades

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. reported that Chief Scientific Officer David Bredt sold a total of 8,500 shares of common stock on September 15, 2025, in open-market or private transactions under a Rule 10b5-1 trading plan adopted on December 12, 2024. The sales were executed at weighted-average prices of $23.8841 and $24.6583 per share across multiple trades at prices ranging from $23.42 to $24.41 and from $24.42 to $24.90. Following these sales, Bredt held 418,142 shares of common stock directly.

Insights

Securities Analyst

TL;DR: Officer sold 8,500 RAPP shares under a pre-established 10b5-1 plan; transactions were disclosed promptly by Form 4.

The sales total 8,500 shares executed on 09/15/2025 in two groups with weighted-average prices of $23.8841 and $24.6583. The use of a Rule 10b5-1 trading plan indicates the trades were pre-authorized on December 12, 2024, which typically reduces the likelihood of opportunistic timing. The Form 4 shows beneficial ownership figures after each reported transaction (421,544 and 418,142 shares), and the filing was signed by an attorney-in-fact on 09/17/2025. For investors, this is a routine insider sale disclosure rather than an operational update.

Corporate Governance Expert

TL;DR: Insider disposals were processed through an established 10b5-1 plan and properly reported.

The reporting person is identified as an officer (Chief Scientific Officer) and the filing documents that the transactions were executed pursuant to a Rule 10b5-1 plan adopted on December 12, 2024. The Form 4 includes the required weighted-average prices and an undertaking to provide per-price sale breakdowns upon request. The signature by an attorney-in-fact on 09/17/2025 is consistent with authorized filing practices. This filing meets disclosure requirements for officer trading activity.

Insider Trade Summary

Net Seller: 8,500 shares

Net Sell 2 txns

Insider Bredt David

Role Chief Scientific Officer

Sold 8,500 shs ($206K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,098	$23.8841	$122K
Sale	Common Stock	3,402	$24.6583	$84K

Holdings After Transaction: Common Stock — 418,142 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.42 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.42 to $24.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Shares sold (first transaction): 5098 shares Shares sold (second transaction): 3402 shares Total shares sold: 8500 shares +4 more

7 metrics

Shares sold (first transaction) 5098 shares Common stock sale on September 15, 2025 at weighted-average $23.8841 per share

Shares sold (second transaction) 3402 shares Common stock sale on September 15, 2025 at weighted-average $24.6583 per share

Total shares sold 8500 shares Aggregate of two non-derivative sales reported for September 15, 2025

Post-transaction holdings 418,142 shares Direct common stock holdings by David Bredt after the reported sales

Weighted-average sale price (first) $23.8841 per share Multiple trades at prices between $23.42 and $24.41 per share

Weighted-average sale price (second) $24.6583 per share Multiple trades at prices between $24.42 and $24.90 per share

10b5-1 plan adoption date December 12, 2024 Date the Rule 10b5-1 trading plan governing these transactions was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction, Chief Scientific Officer

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction regulatory

"Sale in open market or private transaction"

Chief Scientific Officer technical

"Bredt David ... officer_title: Chief Scientific Officer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 09/17/2025 - 04:15 PM Learn about SEC filing dates

FAQ

How many RAPP shares did David Bredt sell on September 15, 2025?

David Bredt sold a total of 8,500 shares of Rapport Therapeutics common stock on September 15, 2025. The sales were split into two transactions of 5,098 and 3,402 shares at weighted-average prices of $23.8841 and $24.6583 per share.

What Rule 10b5-1 trading plan is mentioned in the RAPP Form 4?

The transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024. This pre-arranged plan allows trades to occur on a scheduled basis, reducing the significance of the timing of these sales for informational or sentiment purposes.

What is David Bredt’s remaining RAPP shareholding after these sales?

Following the reported transactions, David Bredt directly held 418,142 shares of Rapport Therapeutics common stock. This post-transaction holding reflects his continuing equity position as Chief Scientific Officer of the company after selling 8,500 shares.

At what prices were the RAPP shares sold in the September 15, 2025 transactions?

The weighted-average sale prices were $23.8841 and $24.6583 per share. The shares were sold in multiple trades at prices ranging from $23.42 to $24.41 and from $24.42 to $24.90 per share, as disclosed in the footnotes.

Were the RAPP share sales by David Bredt open-market transactions?

The Form 4 describes each transaction as a sale in open market or private transaction. While the exact venue is not specified, this language indicates the shares were sold outside of derivative exercises or gifts, as standard share sales.

What additional price detail did Rapport Therapeutics disclose for these RAPP trades?

The company disclosed that reported prices are weighted averages, with shares sold in multiple transactions. Trades occurred at prices from $23.42 to $24.41 and from $24.42 to $24.90, and full price breakdowns are available upon request to interested parties.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bredt David

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S(1)		5,098	D	$23.8841(2)	421,544	D
Common Stock	09/15/2025		S(1)		3,402	D	$24.6583(3)	418,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.42 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.42 to $24.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.